Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Visceral fat dysfunction is positively associated with hypogonadism in Chinese men.

Scientific reports·2016
Same author

Fingerprint Analysis of Desmodium Triquetrum L. Based on Ultra Performance Liquid Chromatography with Photodiode Array Detector Combined with Chemometrics Methods.

Journal of chromatographic science·2016
Same author

Neck circumference as an independent indicator to non-alcoholic fatty liver disease in non-obese men.

Nutrition & metabolism·2016
Same author

Associations between implementation characteristics and evidence-based practice sustainment: a study of the Adolescent Community Reinforcement Approach.

Implementation science : IS·2015
Same author

A pre-post pilot study of peer nutritional counseling and food insecurity and nutritional outcomes among antiretroviral therapy patients in Honduras.

BMC nutrition·2015
Same author

MAPKs and Hsc70 are critical to the protective effect of molecular hydrogen during the early phase of acute pancreatitis.

The FEBS journal·2015

相关实验视频

Updated: Jun 24, 2025

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K

CG001是一种针对C3b的补充抑制剂,阻断了3个补充途径:开发和临床前评估.

Ling Li1, Peipei Ding1, Yanrong Dong2

  • 1Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.

Blood advances
|June 12, 2024
PubMed
概括

一种新型的融合蛋白,CG001,通过准C3b,强烈抑制所有三种补充通路. 这种补充抑制剂在疾病模型中表现出治疗效果,并在临床前评估中显示出有利的安全性.

更多相关视频

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

相关实验视频

Last Updated: Jun 24, 2025

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

科学领域:

  • 免疫学 免疫学 免疫学
  • 生物化学 生物化学
  • 药物开发 药物开发

背景情况:

  • 不调节的补充激活与许多人类疾病有关.
  • 越来越需要有效的补充抑制剂来治疗这些疾病.

研究的目的:

  • 开发一种新的,强大的抑制剂,针对所有三种补充通路.
  • 为了评估开发的抑制剂的治疗疗效和安全性,CG001.

主要方法:

  • 开发一种人类衍生的融合蛋白 (CRIg-FH-Fc) x2,称为CG001,准C3b.
  • 评估CG001在所有补体通路中的抑制活性.
  • 在补充介导疾病的小鼠和老鼠模型中评估治疗效果.
  • 在老鼠和Cynomolgus子中进行药理和毒理评估.

主要成果:

  • CG001通过通过CRIg和H因子域与C3b协同结合,强烈抑制了所有三个补充通路.
  • 聚变蛋白在血液溶解性贫血和血球膜炎的模型中显示出治疗效果.
  • 临床前研究显示了类似抗体的药物动力学特征,没有可观察到的毒性作用.

结论:

  • CG001是一种强效的双重作用补充剂抑制剂,具有有前途的安全性.
  • 开发的融合蛋白具有在补充介导疾病中临床应用的巨大潜力.